Megasuuuuuuuuuperabsturzlooseraktien 2004 !!!!!!!!!!!!! - 500 Beiträge pro Seite

[fonx]

Aber welche????? Von welchen sollte man unbedingt die Finger lassen,im Jahr 2004??????? FONX

[NIXLOS]

@fonx , auf jeden fall von 631629 , die gehen als erste insolvenz !!!!
ne arme sau bist du dann und fällst uns allen zur last !

[againstfotsch]

hightechs - bewertung bei den meisten schon wieder viel zu hoch!
interessanter ist doch welche werden steigen?! die umweltaktien sind in 2003 ziemlich schlecht gelaufen - da besteht nachholbedarf!

gruß
af

[mattien]

comroad

[mattien]

worldcom

[mattien]

kaufen beate uhse

[fonx]

@Nixlos,Du wirst noch bittere Tränen weinen,hahahaha, Aber alles gute Dir,FONX

[w8270]

Wenn schon einer im OTC-BB einen Thread eröffnet

der hat doch schon zu 90% in die Schei... gegriffen

[fonx]

Auch aus Scheiße kann man Geld machen,FONX

[js200]

@W8270

Warum schaust du dich denn hier um

JS200

[BIOMIRA]

Biomira BIOM



http://biomira.com/news/detailNewsRelease/178/
News Release
BIOMIRA OUTLINES MILESTONES FOR 2004 - BLP25 Liposomal Vaccine Phase IIb Results Due End Q1/2004

EDMONTON, ALBERTA, CANADA: December 19, 2003
EDMONTON, ALBERTA, Canada — December 19, 2003 — Biomira Inc. (Nasdaq:BIOM) (TSX:BRA) today announced plans and milestones for its product pipeline in 2004. One of the important milestone for 2004 is expected to be the results from the BLP 25 Liposomal vaccine (L-BLP25) Phase IIb study of 171 patients with non-small cell lung cancer. The final analysis is expected toward the end of Q1/2004, with results anticipated to be reported shortly thereafter. Biomira will also continue its analysis of data from its Phase III Theratope® vaccine trial and specifically the subset of women receiving hormonal therapy as part of their initial treatment. The objective here will be to discuss plans with the regulatory authorities, once the strategy has matured.

Biomira and its collaborator, Merck KGaA of Darmstadt, Germany, completed enrolment of the L-BLP25 Phase IIb study in late 2002. Although a final analysis was expected by Q3/2003, clinical events required to trigger the final analysis did not occur as originally projected and the final analysis was moved forward to 2004. The total events required to trigger the final analysis are expected later this month. It is anticipated that it will then take approximately three months to gather the data, have the statisticians conduct the analysis and assemble the Data Safety Monitoring Board, with results to be reported soon thereafter.

Biomira and Merck KGaA are also continuing subset analysis in one pre-stratified subset of more than 300 women who received hormonal treatment following chemotherapy on the Theratope Phase III study of women with metastatic breast cancer. In that subset of women, those on the Theratope arm appeared to show a favourable trend toward improvement in survival.

The Companies have conducted exploratory analyses, that included five additional months of survival follow-up and adjustments including correcting for mis-stratifications and mis-randomizations. From these analyses, results for the subgroup of patients on hormonal therapy showed a median time to disease progression of 8.3 months for patients treated with Theratope versus 5.8 months for those patients on control. The median survival was 38.2 months in the Theratope arm versus 30.7 months in the control, a difference of 7.5 months.

The Companies do not believe the data support a registration at this time, although further analyses are being conducted to determine a mechanism of action to understand why this subset of women appeared to benefit from Theratope. The Companies will decide on further development plans and will likely enter into discussions with regulatory authorities to discuss plans for moving forward, which could include a registration trial, once these additional data are better understood. Discussions with regulatory authorities will likely occur in the second half of 2004.

“Theratope is a relatively non-toxic treatment and in our opinion, the 7.5 months improvement in median survival warrants continuation of analysis,” said Alex McPherson, MD, PhD, President and CEO of Biomira Inc.

Biomira and Merck KGaA continue to enrol women in a Phase II metastatic breast cancer study of Theratope where patients receive either aromatase inhibitors or Faslodex® (fulvestrant), an estrogen-receptor antagonist. This trial is being managed by Merck KGaA’s wholly owned U.S. subsidiary, EMD Pharmaceuticals, Inc. Full enrolment is expected in the first half of 2004. Patients in this trial have a less aggressive disease than those on the Phase III trial. The data should add to our understanding of the performance of Theratope in women with metastatic breast cancer.

Final data from the Phase II Theratope study in colorectal cancer is also expected in the first quarter of 2004.

“We are hopeful that 2004 holds the potential for more compelling data from both L-BLP25 and Theratope that may prove beneficial to our stakeholders – patients, our shareholders and our employees,” said Dr. McPherson. “Should results prove positive, and assuming regulatory approval and marketplace acceptance, growth potential is certainly indicated.”

With the proceeds of a financing totaling approximately U.S. $16.3 million on October 1, 2003, Biomira had approximately U.S. $35.5 million; Cdn.$47.7 million in its treasury. The Company believes this is sufficient capital to fund its current development plans through 2004. However, if decisions are made to commence future Phase III trials for either L-BLP25 or Theratope, further funding may be required.

The Companies

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira’s commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People™.

Merck KGaA was founded in 1668 and has positioned itself to be on the cutting edge of cancer research with an oncology portfolio based on four technology platforms – monoclonal antibodies, vaccines, immunocytokines and angiogenesis inhibitors.

# # #

Biomira Company Contacts:
Bill Wickson Jane Tulloch

Manager, Public Relations Director, Investor Relations

[phone] [phone]

[fonx]

Aha,also Looseraktie,FONX

[laledu]

Eine eindeutige Loseraktie ist Indo-Pacific Energy Ltd. (INDOF) Neuseeland

Auf alle Fälle habe ich sie nicht, leider!
LALEDU